Abstract
Pre-licensure clinical trials for the BNT162b2 COVID-19 vaccine showed high efficacy among adolescents.1 Similarly, post-licensure studies in this population found high mRNA vaccine effectiveness against both SARS-CoV-2 infection and hospitalisation during the pre-omicron period.2,3 However, emergence of the omicron variant in November, 2021, as well as later omicron subvariants, resulted in decreased COVID-19 vaccine effectiveness and more rapid waning of protection, particularly against infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
